Immunovant

IMVT

Market cap $8.27B

Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock?

IMVT shares climb as IMVT-1402 posts encouraging data, advances across autoimmune diseases and benefits from a cash runway extending through launch.

Immunovant's underlying bull case has now moved away from batoclimab and toward IMVT-1402. This newer asset has encouraging data for difficult-to-treat RA. By week 16, 72.7% of hard-to-treat RA patients had good responses with IMVT-1402. IMVT also has a solid balance sheet this time around. And management believes its runway is sufficient through their next readouts.

Roivant (ROIV) remains a Buy as its unique 'vant' structure rapidly advances and monetizes blockbuster assets, notably through Immunovant's IMVT-1402 in rheumatoid arthritis. IMVT-1402 delivered strong Phase 2 efficacy in difficult-to-treat rheumatoid arthritis, with ACR20/50/70 rates of 72.7%, 54.5%, and 35.8%, respectively. ROIV's financial position is robust, ending the quarter with $4.3 billion in cash and a management-asserted runway to profitability.

Immunovant Inc (NASDAQ:IMVT) on Wednesday posted a wider fourth‑quarter loss than analysts expected.

Immunovant stock jumps 35% as strong early IMVT-1402 data in rheumatoid arthritis boosts confidence despite a wider Q4 loss.

Immunovant Inc (NASDAQ:IMVT) shares are trading higher on Wednesday even though the company posted a wider fourth‑quarter loss than analysts expected.

Immunovant reports clinically meaningful trial results for its lead drug candidate. That's good news for Roivant Sciences.

Roivant executives used the company's fourth-quarter and fiscal-year earnings call to highlight new clinical data from its development portfolio, upcoming readouts and its strengthened balance sheet following a settlement with Moderna.

Immunovant stock shot to an 18-month high Wednesday on "highly compelling" results for its experimental rheumatoid arthritis treatment.